Ascendis Pharma Reports Strong Two-Year Data for Approved Achondroplasia Drug TransCon CNP

summarizeSummary

Ascendis Pharma announced positive two-year clinical trial data for its FDA-approved achondroplasia treatment, TransCon CNP, demonstrating sustained growth improvements and a favorable safety profile.

check_boxKey Events

• Positive Two-Year Trial Data

  New data from the pivotal ApproaCH Trial for TransCon CNP (navepegritide) showed children maintained consistent improvements in growth through Week 104.

• Improved Body Proportionality

  Patients treated with TransCon CNP demonstrated further improvement in upper-to-lower body segment ratio during the second year of treatment.

• Favorable Safety Profile

  TransCon CNP was generally well-tolerated over two years, with most adverse events being mild or moderate and no treatment discontinuations due to adverse events.

• Supports European Regulatory Review

  This long-term efficacy and safety data strengthens the drug's profile as its Marketing Authorization Application is currently under review by the European Medicines Agency.

auto_awesomeAnalysis

Ascendis Pharma's 6-K filing details positive two-year data from the pivotal ApproaCH Trial for TransCon CNP (YUVIWEL®), an already FDA-approved treatment for achondroplasia. The data reinforces the drug's long-term efficacy and safety profile, showing sustained improvements in growth and body proportionality, alongside good tolerability. This strong confirmatory data is crucial for the drug's commercial success and provides significant support for its ongoing Marketing Authorization Application review by the European Medicines Agency, with a decision anticipated in Q4 2026. While the news was released earlier today via GlobeNewswire, this 6-K serves as the official SEC disclosure, solidifying the positive clinical update.